Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine.
Primary factors that influence virus burden during human immunodeficiency virus type 1 (HIV-1) disease progression remain a fundamental issue in pathogenesis. Because pneumococcal vaccine is routinely given to HIV-1-infected patients and replication of HIV-1 within CD4 T cells is dependent on the activation state of the cell, it was investigated whether the T cell activation that enhances the immune response to vaccines may also enhance HIV-1 replication. Vaccination of asymptomatic HIV-1-infected patients led to rapid and significant increases in virus burden in some patients. The magnitude of these increases correlated significantly with the extent of the antibody response to the vaccination. Thus, antigenic stimulation by vaccines designed to prevent secondary infections may promote HIV-1 replication in certain patients. These findings provide a window for examining HIV-1 pathogenesis and for determining the appropriate preventive measures against other diseases in HIV-1-infected persons.
Brichacek
B
B
Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA.
Swindells
S
S
Janoff
E N
EN
Pirruccello
S
S
Stevenson
M
M
D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D000907:Antibodies, Bacterial / Q000032:analysis; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology* / Q000821:virology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology / Q000821:virology; D004279:DNA, Viral / Q000032:analysis; D016049:Didanosine / Q000627:therapeutic use; D018450:Disease Progression; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology* / Q000821:virology*; D015497:HIV-1 / Q000254:growth & development* / Q000472:pathogenicity; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D007252:Influenza Vaccines / Q000276:immunology; D008213:Lymphocyte Activation; D008875:Middle Aged; D011008:Pneumococcal Infections / Q000276:immunology* / Q000517:prevention & control*; D011135:Polysaccharides, Bacterial / Q000276:immunology; D011533:Proviruses / Q000235:genetics; D012367:RNA, Viral / Q000032:analysis; D015375:Receptors, Interleukin-2 / Q000276:immunology; D013997:Time Factors; D014611:Vaccination / Q000009:adverse effects; D014612:Vaccines / Q000009:adverse effects* / Q000276:immunology*; D019562:Viral Load; D015215:Zidovudine / Q000627:therapeutic use
D019380:Anti-HIV Agents; D000907:Antibodies, Bacterial; D004279:DNA, Viral; D007074:Immunoglobulin G; D007252:Influenza Vaccines; D011135:Polysaccharides, Bacterial; D012367:RNA, Viral; D015375:Receptors, Interleukin-2; D014612:Vaccines; D015215:Zidovudine; D016049:Didanosine